Product Portfolio |
Becanex secures the future of the Bedrocan brand and Canadian production

Bedrocan remains an independent brand: proven flower quality, new dosage forms for inhalation and oral use.
Berlin, 16 November 2026 – Becanex®, an EU-GMP-certified manufacturer of inhalable standardized cannabis soft extracts with production in Berlin-Adlershof, is acquiring the Bedrocan® brand, including its variety names, and Bedrocan Canada Ltd. Bedrocan Canada holds a licence from Health Canada and remains independent, with its team led by Johan Erkelens. At its production facility in Toronto, all the varieties that Bedrocan has developed over 25 years are grown in close consultation with Johan, Dolf and Jacob Erkelens. The site will be further expanded in the future. Together, the two companies will cover the entire value chain, from dried flower to standardized extract.
For pharmacists and physicians, this means consistent quality and reliable volumes, even as demand grows. Becanex PIEX Bedrocan® 78 % THC, developed together with Bedrocan in 2025, and available in German pharmacies since October 2026, remains on the market, and the portfolio will be expanded to include standardized liquid extracts based on Bedrocan genetics. The Bedrocan flower varieties, including Bedrocan®, Bediol® and Bedrolite®, will also be available in the future.
Becanex manufactures standardized cannabis soft extracts from the Bedrocan varieties. Pharmacists then further process them for individual patient requirements, for example into preparations for inhalation with medical vaporisers or into other dosage forms. This keeps the proven varieties available while allowing the dosage form to be tailored to each therapy, including in countries where patient supply relies mainly on extracts.
In the "Professionals" section at becanex.com, physicians and pharmacists can find flower-to-extract conversion tables, sample formulations, pricing guidance and an overview of the current legal situation in Germany. Becanex medical advisors are available to provide personal support with questions on prescribing and reimbursement.
“Bedrocan set the benchmark for medical cannabis in Europe, and it still holds today. We are taking over not just a brand, but decades of breeding work and a team that knows these varieties. Physicians and pharmacies must be able to rely on their patients continuing to receive the variety they have been stabilised on,” says Sebastian Kamphorst, Managing Director of Becanex GmbH.
About Becanex
Becanex GmbH manufactures standardized cannabis soft and liquid extracts in Berlin-Adlershof in accordance with the Ph. Eur. monograph “Herbal drug extracts” and the German Pharmacopoeia (DAB) monograph “Eingestellter Cannabisextrakt” (standardized cannabis extract) for the preparation of compounded medicines, and markets them as the PIEX product portfolio. The extracts are characterised by a free-flowing viscosity and a representative cannabinoid and terpene profile – the “flower in a bottle”. At its Berlin site, Becanex holds a manufacturing authorisation under Section 13(1) of the German Medicinal Products Act (AMG) and a GMP certificate, and is registered as an active substance manufacturer under Section 64(3g) AMG. www.becanex.com
About Bedrocan
The Erkelens family founded Bedrocan in 1984 and established standardized cannabis flowers as a medicine in Europe: from 2003 in the Dutch medicinal cannabis programme, and from 2007 in other countries as well, including Germany. Today, physicians in more than 15 countries use Bedrocan products. The brand is managed by Becanex.
Contact
Press: Saskia Ganschow · saskia@becanex.com · Tel. +49 30 63 41 85 85
Bedrocan and business partners: Sebastian Kamphorst · sebastian@becanex.com · Tel. +49 30 63 41 85 85
Pharmacies and physicians: Carina Bopf · carina@becanex.com · Tel. +49 30 63 41 85 85



